Detalhe da pesquisa
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256976
2.
Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions.
Pharm Stat
; 22(4): 671-691, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36970778
3.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Br J Cancer
; 119(11): 1401-1409, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30353044
4.
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Lancet
; 388(10063): 2997-3005, 2016 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908454
5.
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
Cancer
; 122(12): 1844-52, 2016 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27062051
6.
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Lancet Oncol
; 14(1): 38-47, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23200175
7.
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 68(6): 1619-28, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21953275